A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 15, Issue 2, 2013, Pages

  Nordberg, Agneta ^a   Ballard, Clive ^b   Bullock, Roger ^c   Darreh Shori, Taher ^a   Somogyi, Monique ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c VICTORIA HOSPITAL   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 BIS(4 ALLYLDIMETHYLAMMONIUMPHENYL)PENTAN 3 ONE DIBROMIDE; 4' ISOPROPYLPHENYLCARBAMATE; ACETYLCHOLINESTERASE; APOLIPOPROTEIN E; BAMBUTEROL; BUTYRYLCHOLINESTERASE K; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CYMSERINE; DONEPEZIL; DYFLOS; ECOTHIOPATE; EDROPHONIUM; EDROPHONIUM CHLORIDE; EPTASTIGMINE; GALANTAMINE; HEPTYLPHYSOSTIGMINE; METRIFONATE; MF 8622; N1 PHENYLETHYLCYMSERINE; N1,N8 BISNORCYMSERINE; NEOSTIGMINE; PHENSERINE; PHYSOSTIGMINE; PHYSOVENINE; PLACEBO; PROFENAMINE; RIVASTIGMINE; TACRINE; THIAPHYSOVENINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC SYNAPSE; CHOLINERGIC TRANSMISSION; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INFUSION; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GENETIC RISK; GENOTYPE; HUMAN; HYDROLYSIS; MEDLINE; NONHUMAN; PARKINSON DISEASE; PARKINSON DISEASE DEMENTIA; PATHOPHYSIOLOGY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT;

EID: 84877665106     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.12r01412     Document Type: Article

References (128)

1. Perry E, Walker M, Grace J, et al. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22(6):273-280. PubMed doi:10.1016/S0166-2236(98)01361-7 ShowAbstract ShowAbstract
2. C. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation. Neurology. 1998; 51(suppl 1):S18-S29. PubMed
3. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1983;219(4589):1184-1190. PubMed doi:10.1126/science.6338589 ShowAbstract ShowAbstract
4. Schumacher M, Camp S, Maulet Y, et al. Primary structure of torpedo californica acetylcholinesterase deduced from its cDNA sequence. Nature. 1986;319(6052):407-409. PubMed doi:10.1038/319407a0 ShowAbstract ShowAbstract
5. Mesulam M, Guillozet A, Shaw P, et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis. 2002;9(1):88-93. PubMed doi:10.1006/nbdi.2001.0462 ShowAbstract ShowAbstract
6. Adem A. Putative mechanisms of action of tacrine in Alzheimer's disease. Acta Neurol Scand Suppl. 1992;85(S139):69-74. PubMed doi:10.1111/j.1600-0404.1992.tb04458.x ShowAbstract ShowAbstract
7. Daikhin Y, Yudkoff M. Compartmentation of brain glutamate metabolism in neurons and glia. JNutr. 2000;130(suppl 4S):1026S-1031S. PubMed ShowAbstract ShowAbstract
8. Messamore E, Warpman U, Ogane N, et al. Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex. Neuropharmacology. 1993;32(8):745-750. PubMed doi:10.1016/0028-3908(93)90182-3 ShowAbstract ShowAbstract
9. Yamada H, Otsuka M, Fujimoto K, et al. Determination of acetylcholine concentration in cerebrospinal fluid of patients with neurologic diseases. Acta Neurol Scand. 1996;93(1):76-78. PubMed doi:10.1111/j.1600-0404.1996.tb00175.x ShowAbstract ShowAbstract
10. Darreh-Shori T, Forsberg A, Modiri N, et al. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging. 2011; 32(12):2320. e15-e32. PubMed
11. Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001;18(12):891-898. PubMed doi:10.2165/00002512-200118120-00001 ShowAbstract ShowAbstract
12. Oda Y, Nakanishi I. The distribution of cholinergic neurons in the human central nervous system. Histol Histopathol. 2000;15(3):825-834. PubMed ShowAbstract ShowAbstract
13. Brimijoin S, Hammond P. Butyrylcholinesterase in human brain and acetylcholinesterase in human plasma: trace enzymes measured by two-site immunoassay. JNeurochem. 1988;51(4):1227-1231. PubMed doi:10.1111/j.1471-4159.1988.tb03091.x ShowAbstract ShowAbstract
14. Green RC, Mesulam MM. Acetylcholinesterase fiber staining in the human hippocampus and parahippocampal gyrus. JComp Neurol. 1988;273(4):488-499. PubMed doi:10.1002/cne.902730405 ShowAbstract ShowAbstract
15. Mesulam MM, Geula C. Acetylcholinesterase-rich neurons of the human cerebral cortex: cytoarchitectonic and ontogenetic patterns of distribution. JComp Neurol. 1991;306(2):193-220. PubMed doi:10.1002/cne.903060202 ShowAbstract ShowAbstract
16. Darvesh S, Grantham DL, Hopkins DA. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. JComp Neurol. 1998;393(3):374-390. PubMed doi:10.1002/(SICI)1096-9861(19980413)393:3<374::AID-CNE8>3.0.CO;2-Z ShowAbstract ShowAbstract
17. Xie W, Stribley JA, Chatonnet A, et al. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. JPharmacol Exp Ther. 2000;293(3):896-902. PubMed ShowAbstract ShowAbstract
18. Li B, Stribley JA, Ticu A, et al. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. JNeurochem. 2000;75(3):1320-1331. PubMed doi:10.1046/j.1471-4159.2000.751320.x ShowAbstract ShowAbstract
19. Mesulam MM, Guillozet A, Shaw P, et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience. 2002;110(4):627-639. PubMed doi:10.1016/S0306-4522(01)00613-3 ShowAbstract ShowAbstract
20. Hartmann J, Kiewert C, Duysen EG, et al. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. JNeurochem. 2007;100(5):1421-1429. PubMed doi:10.1111/j.1471-4159.2006.04347.x ShowAbstract ShowAbstract
21. Inestrosa NC, Alvarez A, Pérez CA, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron. 1996;16(4):881-891. PubMed doi:10.1016/S0896-6273(00)80108-7 ShowAbstract ShowAbstract
22. Diamant S, Podoly E, Friedler A, et al. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci U S A. 2006;103(23):8628-8633. PubMed doi:10.1073/pnas.0602922103 ShowAbstract ShowAbstract
23. UN. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Monit. 2007;13(12):RA214-RA221. PubMed ShowAbstract ShowAbstract
24. Perry EK, Perry RH, Blessed G, et al. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1978;4(4):273-277. PubMed doi:10.1111/j.1365-2990.1978.tb00545.x ShowAbstract ShowAbstract
25. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;308(8000):1403. PubMed doi:10.1016/S0140-6736(76)91936-X ShowAbstract ShowAbstract
26. Whitehouse PJ, Price DL, Struble RG, et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982;215(4537):1237-1239. PubMed doi:10.1126/science.7058341 ShowAbstract ShowAbstract
27. Ciro A, Park J, Burkhard G, et al. Biochemical differentiation of cholinesterases from normal and Alzheimer's disease cortex. Curr Alzheimer Res. 2012; 9(1):138-143. PubMed ShowAbstract ShowAbstract
28. Darreh-Shori T, Brimijoin S, Kadir A, et al. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis. 2006;24(2):326-333. PubMed doi:10.1016/j.nbd.2006.07.013 ShowAbstract ShowAbstract
29. Geula C, Mesulam M. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res. 1989;498(1):185-189. PubMed doi:10.1016/0006-8993(89)90419-8 ShowAbstract ShowAbstract
30. Wright CI, Geula C, Mesulam MM. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol. 1993;34(3):373-384. PubMed doi:10.1002/ana.410340312 ShowAbstract ShowAbstract
31. Geula C, Mesulam MM. Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord. 1995;9(suppl 2):23-28. PubMed doi:10.1097/00002093-199501002-00005 ShowAbstract ShowAbstract
32. Guillozet AL, Smiley JF, Mash DC, et al. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol. 1997;42(6):909-918. PubMed doi:10.1002/ana.410420613 ShowAbstract ShowAbstract
33. Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol. 1994;36(5):722-727. PubMed doi:10.1002/ana.410360506 ShowAbstract ShowAbstract
34. Ruberg M, Rieger F, Villageois A, et al. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease. Brain Res. 1986;362(1):83-91. PubMed doi:10.1016/0006-8993(86)91401-0 ShowAbstract ShowAbstract
35. Ruberg M, Villageois A, Bonnet AM, et al. Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems. JNeurol Neurosurg Psychiatry. 1987;50(5):538-543. PubMed doi:10.1136/jnnp.50.5.538 ShowAbstract ShowAbstract
36. Sirviö J, Soininen HS, Kutvonen R, et al. Acetyl- and butyrylcholinesterase activity in the cerebrospinal fluid of patients with Parkinson's disease. JNeurol Sci. 1987;81(2-3):273-279. PubMed doi:10.1016/0022-510X(87)90102-X ShowAbstract ShowAbstract
37. Maetzler W, Keller S, Michelis J, et al. No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiol Dis. 2009;35(2):296-301. PubMed doi:10.1016/j.nbd.2009.05.014 ShowAbstract ShowAbstract
38. Massoulié J, Bon S. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. Annu Rev Neurosci. 1982;5(1):57-106. PubMed doi:10.1146/annurev.ne.05.030182.000421 ShowAbstract ShowAbstract
39. Arendt T, Brückner MK, Lange M, et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms. Neurochem Int. 1992;21(3):381-396. PubMed doi:10.1016/0197-0186(92)90189-X ShowAbstract ShowAbstract
40. Siek GC, Katz LS, Fishman EB, et al. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain. Biol Psychiatry. 1990;27(6):573-580. PubMed doi:10.1016/0006-3223(90)90524-6 ShowAbstract ShowAbstract
41. Ogane N, Giacobini E, Struble R. Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain. Brain Res. 1992;589(2):307-312. PubMed doi:10.1016/0006-8993(92)91291-L ShowAbstract ShowAbstract
42. Giacobini E. Butyrylcholinesterase: its role in brain function. In: Giacobini E, ed. Butyrylcholinesterase: Its Function and Inhibitors. London, UK: Martin Dunitz; 2003:1-20.
43. Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology. 2003;60(11):1852-1853. PubMed doi:10.1212/01.WNL.0000068336.84399.9E ShowAbstract ShowAbstract
44. Lehmann D, Smith A. Butyrylcholinesterase K variant in Alzheimer's disease. In Giacobini E, ed. Butyrylcholinesterase: Its Function and Inhibitors. London, UK: Martin Dunitz; 2003: 135-148.
45. Bartels CF, Jensen FS, Lockridge O, et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet. 1992;50(5):1086-1103. PubMed ShowAbstract ShowAbstract
46. Lane RM, He Y. Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE ε 4, and hyperhomocysteinemia in neurodegenerative dementias. Med Hypotheses. 2009;73(2):230-250. PubMed doi:10.1016/j.mehy.2009.01.050 ShowAbstract ShowAbstract
47. Lehmann DJ, Nagy Z, Litchfield S, et al. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Hum Genet. 2000;106(4):447-452. PubMed doi:10.1007/s004390000277 ShowAbstract ShowAbstract
48. Ballard C, Morris C, Kalaria R, et al. The K variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients. Dement Geriatr Cogn Disord. 2005;19(5-6):357-360. PubMed doi:10.1159/000084705 ShowAbstract ShowAbstract
49. McIlroy SP, Crawford VL, Dynan KB, et al. Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland. JMed Genet. 2000;37(3):182-185. PubMed doi:10.1136/jmg.37.3.182 ShowAbstract ShowAbstract
50. Raygani AV, Zahrai M, Soltanzadeh A, et al. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease. Neurosci Lett. 2004;371(2-3):142-146. PubMed doi:10.1016/j.neulet.2004.08.057 ShowAbstract ShowAbstract
51. Wiebusch H, Poirier J, Sévigny P, et al. Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet. 1999;104(2):158-163. PubMed doi:10.1007/s004390050929 ShowAbstract ShowAbstract
52. Panegyres PK, Mamotte CD, Vasikaran SD, et al. Butyrycholinesterase K variant and Alzheimer's disease. JNeurol. 1999;246(5):369-370. PubMed doi:10.1007/s004150050365 ShowAbstract ShowAbstract
53. Ghebremedhin E, Thal DR, Schultz C, et al. Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains. Neurosci Lett. 2002;320(1-2):25-28. PubMed doi:10.1016/S0304-3940(02)00014-9 ShowAbstract ShowAbstract
54. Bizzarro A, Guglielmi V, Lomastro R, et al. BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia. JNeural Transm. 2010;117(3):377-383. PubMed doi:10.1007/s00702-009-0358-y ShowAbstract ShowAbstract
55. Sodeyama N, Yamada M, Itoh Y, et al. Association between butyrylcholinesterase K variant and the Alzheimer type neuropathological changes in apolipoprotein E epsilon4 carriers older than 75 years. JNeurol Neurosurg Psychiatry. 1999;67(5):693-694. PubMed doi:10.1136/jnnp.67.5.693 ShowAbstract ShowAbstract
56. Russ C, Powell J, Lovestone S, et al. K variant of butyrycholinesterase and late-onset Alzheimer's disease. Lancet. 1998;351(9106):881. PubMed doi:10.1016/S0140-6736(05)70292-0 ShowAbstract ShowAbstract
57. Singleton AB, Smith G, Gibson AM, et al. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Hum Mol Genet. 1998;7(5):937-939. PubMed doi:10.1093/hmg/7.5.937 ShowAbstract ShowAbstract
58. Yamamoto Y, Yasuda M, Mori E, et al. Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the epsilon4 allele of the apolipoprotein gene in Japanese patients with Alzheimer's disease. JNeurol Neurosurg Psychiatry. 1999;67(1):94-96. PubMed doi:10.1136/jnnp.67.1.94 ShowAbstract ShowAbstract
59. Kehoe PG, Williams H, Holmans P, et al. The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease. JMed Genet. 1998;35(12):1034-1035. PubMed doi:10.1136/jmg.35.12.1034 ShowAbstract ShowAbstract
60. Grubber JM, Saunders AM, Crane-Gatherum AR, et al. Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). Neurosci Lett. 1999;269(2):115-119. PubMed doi:10.1016/S0304-3940(99)00426-7 ShowAbstract ShowAbstract
61. Kim KW, Jhoo JH, Lee JH, et al. Neither the butyrylcholinesterase K variant nor transferrin C2 variant confers a risk for Alzheimer's disease in Koreans. JNeural Transm. 2001;108(10):1159-1166. PubMed doi:10.1007/s007020170005 ShowAbstract ShowAbstract
62. Lane R, He Y, Morris C, et al. BuChE-K and APOE ε4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord. 2009;24(3):392-400. PubMed doi:10.1002/mds.22357 ShowAbstract ShowAbstract
63. Holmes C, Ballard C, Lehmann D, et al. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. JNeurol Neurosurg Psychiatry. 2005;76(5):640-643. PubMed doi:10.1136/jnnp.2004.039321 ShowAbstract ShowAbstract
64. Manoharan I, Kuznetsova A, Fisk JD, et al. Comparison of cognitive functions between people with silent and wild-type butyrylcholinesterase. JNeural Transm. 2007;114(7):939-945. PubMed doi:10.1007/s00702-007-0631-x ShowAbstract ShowAbstract
65. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741-766. PubMed ShowAbstract ShowAbstract
66. Darreh-Shori T, Modiri N, Blennow K, et al. The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging. 2011;32(7):1236-1248. PubMed doi:10.1016/j.neurobiolaging.2009.07.015 ShowAbstract ShowAbstract
67. Mattila KM, Rinne JO, Röyttä M, et al. Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology. JMed Genet. 2000;37(10):766-770. PubMed doi:10.1136/jmg.37.10.766 ShowAbstract ShowAbstract
68. Hiltunen M, Mannermaa A, Helisalmi S, et al. Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients. Neurosci Lett. 1998;250(1):69-71. PubMed doi:10.1016/S0304-3940(98)00453-4 ShowAbstract ShowAbstract
69. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet. 1997;6(11):1933-1936. PubMed doi:10.1093/hmg/6.11.1933 ShowAbstract ShowAbstract
70. Tilley L, Morgan K, Grainger J, et al. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease. Eur J Hum Genet. 1999;7(6):659-663. PubMed doi:10.1038/sj.ejhg.5200351 ShowAbstract ShowAbstract
71. Darreh-Shori T, Siawesh M, Mousavi M, et al. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease. JAlzheimers Dis. 2012;28(2):443-458. PubMed ShowAbstract ShowAbstract
72. Alvarez-Arcaya A, Combarros O, Llorca J, et al. The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women. Acta Neurol Scand. 2000;102(6):350-353. PubMed doi:10.1034/j.1600-0404.2000.102006350.x ShowAbstract ShowAbstract
73. Lane R, Feldman HH, Meyer J, et al. Synergistic effect of apolipoprotein E ε4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. Pharmacogenet Genomics. 2008;18(4):289-298. PubMed doi:10.1097/FPC.0b013e3282f63f29 ShowAbstract ShowAbstract
74. Lee DW, Liu HC, Liu TY, et al. No association between butyrylcholinesterase K-variant and Alzheimer disease in Chinese. Am J Med Genet. 2000;96(2):167-169. PubMed doi:10.1002/(SICI)1096-8628(20000403)96:2<167::AID-AJMG8>3.0.CO;2-0 ShowAbstract ShowAbstract
75. Ki CS, Na DL, Kim JW, et al. No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease. Am J Med Genet. 1999;88(2):113-115. PubMed doi:10.1002/(SICI)1096-8628(19990416)88:2<113::AID-AJMG2>3.0.CO;2-3 ShowAbstract ShowAbstract
76. Crawford F, Fallin D, Suo Z, et al. The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations. Neurosci Lett. 1998;249(2-3):115-118. PubMed doi:10.1016/S0304-3940(98)00423-6 ShowAbstract ShowAbstract
77. Singleton AB, Gibson AM, Edwardson JA, et al. Butyrylcholinesterase K: an association with dementia with Lewy bodies. Lancet. 1998;351(9118):1818. PubMed doi:10.1016/S0140-6736(05)78788-2 ShowAbstract ShowAbstract
78. Greig NH, Sambamurti K, Yu Q-S, et al. Butyrylcholinesterase: its selective inhibition and relevance to Alzheimer's disease therapy. In: Giacobini E, ed. Butyrylcholinesterase: Its Function And Inhibitors. London, UK: Martin Dunitz; 2003:69-90.
79. Ogane N, Giacobini E, Messamore E. Preferential inhibition of acetylcholinesterase molecular forms in rat brain. Neurochem Res. 1992;17(5):489-495. PubMed doi:10.1007/BF00969897 ShowAbstract ShowAbstract
80. Giacobini E, Zhu X D, Williams E, et al. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology. 1996;35(2):205-211. PubMed doi:10.1016/0028-3908(95)00157-3 ShowAbstract ShowAbstract
81. Greig NH, De Micheli E, Holloway HW, et al. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol Scand suppl. 2000;102(s176):74-84. PubMed doi:10.1034/j.1600-0404.2000.00311.x ShowAbstract ShowAbstract
82. Patel N, Spangler EL, Greig NH, et al. Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor. Neuroreport. 1998;9(1):171-176. PubMed doi:10.1097/00001756-199801050-00035 ShowAbstract ShowAbstract
83. Giacobini E, Griffini P, Maggi T, et al. Butyrylcholinesterase: it is important for cortical acetylcholine regulation? Soc Neurosci 1996;22:203
84. Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci U S A. 2005;102(47):17213-17218. PubMed doi:10.1073/pnas.0508575102 ShowAbstract ShowAbstract
85. Galantamine (Razadyne ER) prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021615lbl.pdf. Updated 2005. Accessed October 16, 2012.
86. Aricept Prescribing Information. http://www.aricept.com/assets/pdf/AriceptComboFullPINovember2010.pdf. Updated 2010. Accessed October 16, 2012.
87. Exelon US prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020823s016,021025s008lbl.pdf. Updated June 2006. Accessed October 16, 2012.
88. Exelon Patch. US Prescribing Information. http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf.Updated August 2012. Accessed October 16, 2012.
89. Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs. 1999;12(4):307-323. doi:10.2165/00023210-199912040-00005
90. Ogura H, Kosasa T, Kuriya Y, et al. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol. 2000;22(8):609-613. PubMed doi:10.1358/mf.2000.22.8.701373 ShowAbstract ShowAbstract
91. Cerbai F, Giovannini MG, Melani C, et al. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine. Eur J Pharmacol. 2007;572(2-3):142-150. PubMed doi:10.1016/j.ejphar.2007.06.053 ShowAbstract ShowAbstract
92. Naik RS, Hartmann J, Kiewert C, et al. Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. JPharm Pharm Sci. 2009;12(1):79-85. PubMed ShowAbstract ShowAbstract
93. Furukawa-Hibi Y, Alkam T, Nitta A, et al. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice. Behav Brain Res. 2011;225(1):222-229. PubMed doi:10.1016/j.bbr.2011.07.035 ShowAbstract ShowAbstract
94. Eskander MF, Nagykery NG, Leung EY, et al. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Res. 2005;1060(1-2):144-152. PubMed doi:10.1016/j.brainres.2005.08.039 ShowAbstract ShowAbstract
95. Darreh-Shori T, Modiri N, Nordberg A. ApoE and amyloid beta deflate the cholinergic neurotransmission by boosting the activity and stability of cholinesterases in the brain. Alzheimer's & Dementia. 2009;5(4 suppl):305.
96. Kennedy JS, Polinsky RJ, Johnson B, et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. JClin Psychopharmacol. 1999;19(6):513-521. PubMed doi:10.1097/00004714-199912000-00005 ShowAbstract ShowAbstract
97. Amici S, Lanari A, Romani R, et al. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. Mech Ageing Dev. 2001;122(16):2057-2062. PubMed doi:10.1016/S0047-6374(01)00314-1 ShowAbstract ShowAbstract
98. Parnetti L, Amici S, Lanari A, et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci. 2002;23(suppl 2):S95-S96. PubMed doi:10.1007/s100720200086 ShowAbstract ShowAbstract
99. Nordberg A, Darreh-Shori T, Peskind E, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res. 2009;6(1):4-14. PubMed doi:10.2174/156720509787313961 ShowAbstract ShowAbstract
100. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand. 1998;97(4):244-250. PubMed doi:10.1111/j.1600-0404.1998.tb00645.x ShowAbstract ShowAbstract
101. Parnetti L, Chiasserini D, Andreasson U, et al. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. Acta Neurol Scand. 2011;124(2):122-129. PubMed doi:10.1111/j.1600-0404.2010.01435.x ShowAbstract ShowAbstract
102. Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology. 2002;59(4):563-572. PubMed doi:10.1212/WNL.59.4.563 ShowAbstract ShowAbstract
103. Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. JNeural Transm. 2002;109(7-8):1053-1065. PubMed doi:10.1007/s007020200089 ShowAbstract ShowAbstract
104. Darreh-Shori T, Kadir A, Almkvist O, et al. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging. 2008;29(2):168-184. PubMed doi:10.1016/j.neurobiolaging.2006.09.020 ShowAbstract ShowAbstract
105. Kaasinen V, Någren K, Järvenpää T, et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. JClin Psychopharmacol. 2002;22(6):615-620. PubMed doi:10.1097/00004714-200212000-00012 ShowAbstract ShowAbstract
106. Bohnen NI, Kaufer DI, Hendrickson R, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. JNeurol Neurosurg Psychiatry. 2005;76(3):315-319. PubMed doi:10.1136/jnnp.2004.038729 ShowAbstract ShowAbstract
107. Kadir A, Darreh-Shori T, Almkvist O, et al. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl). 2007;191(4):1005-1014. PubMed doi:10.1007/s00213-007-0725-z ShowAbstract ShowAbstract
108. Kadir A, Darreh-Shori T, Almkvist O, et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging. 2008;29(8):1204-1217. PubMed doi:10.1016/j.neurobiolaging.2007.02.020 ShowAbstract ShowAbstract
109. Keller C, Kadir A, Forsberg A, et al. Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. JAlzheimers Dis. 2011;24(1):109-123. PubMed ShowAbstract ShowAbstract
110. Stefanova E, Wall A, Almkvist O, et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. JNeural Transm. 2006;113(2):205-218. PubMed doi:10.1007/s00702-005-0312-6 ShowAbstract ShowAbstract
111. Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009;(2):CD001191. PubMed ShowAbstract ShowAbstract
112. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;(1):CD001747. PubMed ShowAbstract ShowAbstract
113. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD001190. PubMed ShowAbstract ShowAbstract
114. Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2000;(4):CD001191. PubMed
115. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2005;21(8):1317-1327. PubMed doi:10.1185/030079905X56565 ShowAbstract ShowAbstract
116. Auriacombe S, Pere JJ, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002;18(3):129-138. PubMed doi:10.1185/030079902125000471 ShowAbstract ShowAbstract
117. Bartorelli L, Giraldi C, Saccardo M, et al; Upgrade Study Group. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin. 2005;21(11):1809-1818. PubMed doi:10.1185/030079905X65655 ShowAbstract ShowAbstract
118. Darvesh S, MacKnight C, Rockwood K. Butyrylcholinesterase and cognitive function. Int Psychogeriatr. 2001;13(4):461-464. PubMed doi:10.1017/S1041610201007876 ShowAbstract ShowAbstract
119. Ballard C, Perry EK. The role of butyrylcholinesterase in Alzheimer's disease. In: Giacobini E, ed. Butyrylcholinesterase: Its Function And Inhibitors. London, UK: Martin Dunitz; 2003: 123-134.
120. O'Brien KK, Saxby BK, Ballard CG, et al. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics. 2003;13(4):231-239. PubMed doi:10.1097/00008571-200304000-00008 ShowAbstract ShowAbstract
121. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318(7184):633-638. PubMed doi:10.1136/bmj.318.7184.633 ShowAbstract ShowAbstract
122. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1:55-65.
123. Feldman HH, Lane R; Study 304 Group. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. JNeurol Neurosurg Psychiatry. 2007;78:1056-1063. PubMed doi:10.1136/jnnp.2006.099424 ShowAbstract ShowAbstract
124. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int J Geriatr Psychopharmacol. 1998;1(suppl 1):S26-S34.
125. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22(5):456-467. PubMed doi:10.1002/gps.1788 ShowAbstract ShowAbstract
126. Lane RM, He Y. Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype [published online ahead of print March 6, 2012]. Alzheimers Dement. 2012. PubMed doi:10.1016/j.jalz.2010.12.005 ShowAbstract ShowAbstract
127. Bullock R, Bergman H, Touchon J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin. 2006;22(3):483-494. PubMed doi:10.1185/030079906X89685 ShowAbstract ShowAbstract
128. Blesa R, Bullock R, He Y, et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genomics. 2006;16(11):771-774. PubMed doi:10.1185/030079906X89685c PubMed ShowAbstract ShowAbstract